On March 12, 2025 HoneyBear Biosciences Inc. (HoneyBear), recently named ‘Best ADC Developer in Taiwan’ at the 2025 Asia Pacific Biopharma Excellence Awards (ABEA) reported that we have secured two licenses from Singapore’s Agency for Science, Technology and Research (A*STAR) to develop Antibody-Radionuclide Conjugates (ARCs) to tackle cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The two licenses include:
An exclusive license to develop and utilise antibodies created by the A*STAR Singapore Immunology Network (A*STAR SIgN) for ARC development.
A non-exclusive license for the multicistronic expression vector technology from the A*STAR Bioprocessing Technology Institute (A*STAR BTI), which will be utilised for the efficient production of the antibody.
By combining HoneyBear’s patented CoNectar technology with A*STAR’s technologies, we aim to revolutionise next-generation ARCs to a new era. This advanced approach precisely delivers radiation to tumour cells, enhancing treatment effectiveness while minimising harm to healthy tissues. As a result, patients may benefit from fewer side effects, better treatment outcomes, and an improved quality of life during cancer therapy. Together, these efforts will help develop cutting-edge therapies that address critical unmet medical needs, offering new hope to patients worldwide.
(Press release, HoneyBear Biosciences, MAR 12, 2025, View Source [SID1234664772])